CL2003002639A1 - Anticuerpo humanizado que se une a cd20 humano, acido nucleico que lo codifica; vector; celula huesped; composicion; y articulo de manufactura que lo contiene, usos del anticuerpo. - Google Patents

Anticuerpo humanizado que se une a cd20 humano, acido nucleico que lo codifica; vector; celula huesped; composicion; y articulo de manufactura que lo contiene, usos del anticuerpo.

Info

Publication number
CL2003002639A1
CL2003002639A1 CL200302639A CL2003002639A CL2003002639A1 CL 2003002639 A1 CL2003002639 A1 CL 2003002639A1 CL 200302639 A CL200302639 A CL 200302639A CL 2003002639 A CL2003002639 A CL 2003002639A CL 2003002639 A1 CL2003002639 A1 CL 2003002639A1
Authority
CL
Chile
Prior art keywords
antibody
codifies
vector
article
manufacture
Prior art date
Application number
CL200302639A
Other languages
English (en)
Spanish (es)
Inventor
Camellia W Chan Andrew C Adams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36166967&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2003002639(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2003002639A1 publication Critical patent/CL2003002639A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CL200302639A 2002-12-16 2003-12-16 Anticuerpo humanizado que se une a cd20 humano, acido nucleico que lo codifica; vector; celula huesped; composicion; y articulo de manufactura que lo contiene, usos del anticuerpo. CL2003002639A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43411502P 2002-12-16 2002-12-16

Publications (1)

Publication Number Publication Date
CL2003002639A1 true CL2003002639A1 (es) 2005-04-08

Family

ID=36166967

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302639A CL2003002639A1 (es) 2002-12-16 2003-12-16 Anticuerpo humanizado que se une a cd20 humano, acido nucleico que lo codifica; vector; celula huesped; composicion; y articulo de manufactura que lo contiene, usos del anticuerpo.

Country Status (6)

Country Link
CN (6) CN1751236A (no)
CA (1) CA2835591A1 (no)
CL (1) CL2003002639A1 (no)
NO (1) NO338313B1 (no)
TN (1) TNSN06133A1 (no)
ZA (1) ZA200504221B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
MX2010007935A (es) * 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
CN102439163A (zh) * 2009-02-16 2012-05-02 拜奥雷克斯治疗公司 人源化抗cd20抗体及使用方法
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
CN102190728B (zh) 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
KR102109172B1 (ko) * 2011-02-15 2020-05-12 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
LT2771364T (lt) * 2011-10-27 2019-09-10 Genmab A/S Heterodimerinių baltymų gamyba
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN103880957B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l1h1及其应用
CN103936855B (zh) * 2014-03-27 2016-05-04 合肥泰瑞生物技术有限公司 抗cd20抗原的抗体l4h5及其应用
CN103897059B (zh) * 2014-03-27 2016-03-23 中国人民解放军军事医学科学院生物工程研究所 抗cd20抗原的抗体l5h7及其应用
CN103880958B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l4h6及其应用
CN103936858B (zh) * 2014-03-27 2016-05-04 安徽大学 抗cd20抗原的抗体l5h6及其应用
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof
CA3033505A1 (en) * 2016-08-11 2018-02-15 The Jackson Laboratory Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
CN106872713A (zh) * 2016-12-27 2017-06-20 许洋 一种微量蛋白质原位检测的免疫质谱试剂盒及制备方法
CN108531561A (zh) * 2017-03-01 2018-09-14 云南序源生物技术开发有限公司 一种快速检测用于鉴定y染色体单倍型谱系的snp特征位点的试剂盒及方法
CN111705084B (zh) * 2020-08-18 2020-12-08 江苏集萃药康生物科技有限公司 一种稳定表达荧光素酶及人cd20敲除鼠cd20的小鼠b细胞淋巴瘤细胞系构建方法
CN114990128A (zh) * 2021-06-16 2022-09-02 百奥赛图(北京)医药科技股份有限公司 Cd20基因人源化非人动物的构建方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
MY136203A (en) * 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof

Also Published As

Publication number Publication date
CN101418044A (zh) 2009-04-29
CN101418044B (zh) 2014-03-12
TNSN06133A1 (en) 2007-11-15
CN1748143A (zh) 2006-03-15
CN1747969A (zh) 2006-03-15
CN100460421C (zh) 2009-02-11
CN101418045A (zh) 2009-04-29
CA2835591A1 (en) 2004-07-08
NO20150245L (no) 2005-08-31
NO338313B1 (no) 2016-08-08
CN101418043A (zh) 2009-04-29
ZA200504221B (en) 2006-08-30
CN1751236A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
CL2003002639A1 (es) Anticuerpo humanizado que se une a cd20 humano, acido nucleico que lo codifica; vector; celula huesped; composicion; y articulo de manufactura que lo contiene, usos del anticuerpo.
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
EA200870132A1 (ru) Антитела против cd19 с пониженной иммуногенностью
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
NO20070924L (no) Materiale, samt anvendelse av samme.
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
PE20110593A1 (es) Anticuerpos multiespecificos
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
WO2006076691A8 (en) Irta-2 antibodies and their uses
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
WO2005097185A3 (en) Irta-5 antibodies and their uses